Literature DB >> 33396725

Recent Insights into Therapy Resistance in Osteosarcoma.

Zachary D Prudowsky1,2, Jason T Yustein1,2.   

Abstract

Osteosarcoma, the most common bone malignancy of childhood, has been a challenge to treat and cure. Standard chemotherapy regimens work well for many patients, but there remain minimal options for patients with progressive or resistant disease, as clinical trials over recent decades have failed to significantly improve survival. A better understanding of therapy resistance is necessary to improve current treatments and design new strategies for future treatment options. In this review, we discuss known mechanisms and recent scientific advancements regarding osteosarcoma and its patterns of resistance against chemotherapy, radiation, and other newly-introduced therapeutics.

Entities:  

Keywords:  autophagy; chemotherapy resistance; hypoxia; osteosarcoma; radiation resistance; tumor microenvironment

Year:  2020        PMID: 33396725     DOI: 10.3390/cancers13010083

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  22 in total

1.  Reinforcement of Sorafenib Anti-osteosarcoma Effect by Amentoflavone Is Associated With the Induction of Apoptosis and Inactivation of ERK/NF-κB.

Authors:  Chun-Min Su; Chi-Huan Li; Meng-Chu Huang; Po-Fu Yueh; Fei-Ting Hsu; Rong-Fong Lin; Li-Cho Hsu
Journal:  In Vivo       Date:  2022 May-Jun       Impact factor: 2.406

Review 2.  Bifunctional scaffolds for tumor therapy and bone regeneration: Synergistic effect and interplay between therapeutic agents and scaffold materials.

Authors:  Jiongpeng Yuan; Zhaoyi Ye; Yaoxun Zeng; Zhenxing Pan; ZhenZhen Feng; Ying Bao; Yushan Li; Xujie Liu; Yan He; Qingling Feng
Journal:  Mater Today Bio       Date:  2022-06-09

3.  Hydroxytyrosol Prevents Doxorubicin-Induced Oxidative Stress and Apoptosis in Cardiomyocytes.

Authors:  Ivana Sirangelo; Maria Liccardo; Clara Iannuzzi
Journal:  Antioxidants (Basel)       Date:  2022-05-30

Review 4.  The Macrophage-Osteoclast Axis in Osteoimmunity and Osteo-Related Diseases.

Authors:  Yao Yao; Xiaoyu Cai; Fujia Ren; Yiqing Ye; Fengmei Wang; Caihong Zheng; Ying Qian; Meng Zhang
Journal:  Front Immunol       Date:  2021-03-31       Impact factor: 7.561

5.  Development and Verification of a Hypoxic Gene Signature for Predicting Prognosis, Immune Microenvironment, and Chemosensitivity for Osteosarcoma.

Authors:  Fengfeng Wu; Juntao Xu; Mingchao Jin; Xuesheng Jiang; Jianyou Li; Xiongfeng Li; Zhuo Chen; Jiangbo Nie; Zhipeng Meng; Guorong Wang
Journal:  Front Mol Biosci       Date:  2022-01-05

6.  Development of a Nomogram for Predicting the Efficacy of Preoperative Chemotherapy in Osteosarcoma.

Authors:  Qingshan Huang; Chenglong Chen; Jingbing Lou; Yi Huang; Tingting Ren; Wei Guo
Journal:  Int J Gen Med       Date:  2021-08-26

7.  Data-Driven Mathematical Model of Osteosarcoma.

Authors:  Trang Le; Sumeyye Su; Arkadz Kirshtein; Leili Shahriyari
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

Review 8.  Targeting ferroptosis in osteosarcoma.

Authors:  Jiazheng Zhao; Yi Zhao; Xiaowei Ma; Benzheng Zhang; Helin Feng
Journal:  J Bone Oncol       Date:  2021-07-12       Impact factor: 4.072

9.  Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study.

Authors:  Zhiyong Liu; Songtao Gao; Liangyu Zhu; Jiaqiang Wang; Peng Zhang; Po Li; Fan Zhang; Weitao Yao
Journal:  Cancer Med       Date:  2021-09-26       Impact factor: 4.452

10.  A Hypoxia Gene-Based Signature to Predict the Survival and Affect the Tumor Immune Microenvironment of Osteosarcoma in Children.

Authors:  Feng Jiang; Xiao-Lin Miao; Xiao-Tian Zhang; Feng Yan; Yan Mao; Chu-Yan Wu; Guo-Ping Zhou
Journal:  J Immunol Res       Date:  2021-07-15       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.